– Antiretroviral, HIV-1 non nucleoside reverse transcriptase inhibitor
– HIV-1 infection, in combination with other antiretroviral drugs
Forms and strengths
– 200 mg breakable tablet, 200 mg capsule and 200 mg and 600 mg tablets
– The dose is given once daily at bedtime.
Child 3 years and over and adult:
|Weight||Dose||Tablets or capsules|
|10 to < 14 kg||200 mg||1 tablet 200 mg or 1 capsule 200 mg|
|14 to < 25 kg||300 mg||1 tablet 200 mg + ½ tablet 200 mg|
|25 to < 40 kg||400 mg||2 tablets 200 mg or 2 capsules 200 mg|
|≥ 40 kg||600 mg||1 tablet 600 mg|
– Depending on the efficacy and tolerance of efavirenz.
Contra-indications, adverse effects, precautions
– Do not administer to children under 3 years.
– Avoid administration in patients with severe hepatic impairment.
– Avoid combination with drugs that prolong QT interval: amiodarone, chloroquine, co-artemether, fluconazole, haloperidol, hydroxyzine, mefloquine, moxifloxacin, ondansetron, pentamidine, quinine, etc.
– Administer with caution to patients with psychiatric disorders (or history of) or epilepsy.
– Do not combine with amodiaquine.
– May cause:
• neurological disorders (dizziness, insomnia, drowsiness, abnormal dreaming, impaired concentration, seizures);
• psychiatric disorders (severe depression, suicidal ideation);
• raised liver enzymes (ALAT);
• skin reactions, possibly severe (Stevens-Johnson syndrome).
– Efavirenz reduces the efficacy of oral contraceptives: use a non-hormonal contraception or injectable medroxyprogesterone or an oral contraceptive containing 50 micrograms ethinylestradiol per tablet.
– Pregnancy: no contra-indication
– Storage: below 25 °C